JP4854851B2 - 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 - Google Patents

改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 Download PDF

Info

Publication number
JP4854851B2
JP4854851B2 JP2000575546A JP2000575546A JP4854851B2 JP 4854851 B2 JP4854851 B2 JP 4854851B2 JP 2000575546 A JP2000575546 A JP 2000575546A JP 2000575546 A JP2000575546 A JP 2000575546A JP 4854851 B2 JP4854851 B2 JP 4854851B2
Authority
JP
Japan
Prior art keywords
leptin
protein
amino acid
bioconjugate
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000575546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527052A (ja
JP2002527052A5 (cg-RX-API-DMAC7.html
Inventor
ゲツグ,コリン
キンストラー,オーラフ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2002527052A publication Critical patent/JP2002527052A/ja
Publication of JP2002527052A5 publication Critical patent/JP2002527052A5/ja
Application granted granted Critical
Publication of JP4854851B2 publication Critical patent/JP4854851B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2000575546A 1998-10-14 1999-10-13 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 Expired - Lifetime JP4854851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/172,644 1998-10-14
US09/172,644 US6420339B1 (en) 1998-10-14 1998-10-14 Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PCT/US1999/024401 WO2000021574A2 (en) 1998-10-14 1999-10-13 Site-directed dual pegylation of proteins

Publications (3)

Publication Number Publication Date
JP2002527052A JP2002527052A (ja) 2002-08-27
JP2002527052A5 JP2002527052A5 (cg-RX-API-DMAC7.html) 2006-11-30
JP4854851B2 true JP4854851B2 (ja) 2012-01-18

Family

ID=22628578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000575546A Expired - Lifetime JP4854851B2 (ja) 1998-10-14 1999-10-13 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化

Country Status (8)

Country Link
US (1) US6420339B1 (cg-RX-API-DMAC7.html)
EP (1) EP1121155B1 (cg-RX-API-DMAC7.html)
JP (1) JP4854851B2 (cg-RX-API-DMAC7.html)
AT (1) ATE463260T1 (cg-RX-API-DMAC7.html)
AU (1) AU757860B2 (cg-RX-API-DMAC7.html)
CA (1) CA2345027C (cg-RX-API-DMAC7.html)
DE (1) DE69942231D1 (cg-RX-API-DMAC7.html)
WO (1) WO2000021574A2 (cg-RX-API-DMAC7.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
EP1151102B1 (en) * 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
KR100401296B1 (ko) * 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR100961859B1 (ko) * 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
WO2003093433A2 (en) * 2002-05-02 2003-11-13 Regents Of The University Of Minnesota Fibrin-based biomatrix
AU2003233119A1 (en) * 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
EP2330213A1 (en) * 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7587286B2 (en) * 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
MXPA06010764A (es) * 2004-03-23 2006-12-15 Amgen Inc Metodos y composiciones de proteinas quimicamente modificadas.
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
JP4990792B2 (ja) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−tRNAシンテターゼの組成物およびこの使用
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
KR20080027291A (ko) * 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
CN101511856B (zh) 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
AR071169A1 (es) * 2008-03-31 2010-06-02 Council Scient Ind Res Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
WO2009149379A2 (en) * 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
BRPI0921640A2 (pt) * 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
KR20120103606A (ko) * 2009-11-04 2012-09-19 얀센 파마슈티카 엔.브이. 스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス,インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
AU2012210624A1 (en) * 2011-01-26 2013-07-11 Novo Nordisk A/S Leptin derivatives
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
PT3045183T (pt) * 2011-03-11 2018-11-02 Genzyme Corp Apelina peguilada e suas utilizações
EP2693887B1 (en) 2011-04-06 2020-10-28 The Board of Regents of the University of Texas System Modulating bacterial mam polypeptides in pathogenic disease
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US20130022592A1 (en) 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
CA2867611A1 (en) * 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c1-inhibitors
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US9789156B2 (en) 2013-03-11 2017-10-17 Dana-Farber Cancer Institute, Inc. Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ph20玻尿酸酶變異體及其用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
PT3074033T (pt) 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR20210057124A (ko) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 용도
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス,インコーポレイテッド インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
US20250341516A1 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Compositions for use with multiple fluorophores and methods of using
WO2025250943A1 (en) * 2024-05-30 2025-12-04 Penguin Bio Corp. Leptin variants and methods of use thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034885A2 (en) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Biologically active peptide fragments of ob protein
JPH093098A (ja) * 1995-05-05 1997-01-07 F Hoffmann La Roche Ag 組換え肥満(ob)蛋白
WO1997024440A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
WO1998024896A2 (en) * 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteins of obese protein

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4695463A (en) 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
HUT62011A (en) 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
EP0725079A1 (en) 1995-01-31 1996-08-07 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
JPH11501297A (ja) 1995-01-31 1999-02-02 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
AU5539596A (en) 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
EP0826045A1 (en) 1995-05-08 1998-03-04 Chiron Corporation Nucleic acids for treating obesity
CA2221824A1 (en) 1995-05-26 1996-11-28 Eli Lilly And Company Rhesus ob protein and dna
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US5581005A (en) 1995-06-16 1996-12-03 The Procter & Gamble Company Method for manufacturing cobalt catalysts
AU6284896A (en) 1995-06-22 1997-01-22 Eli Lilly And Company Obesity protein intermediates and their preparation and use
GB2302559B (en) 1995-06-23 1998-06-03 Draftex Ind Ltd Opening arrangements and methods for closure members
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
WO1997006816A1 (en) 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997016550A1 (en) 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
CA2236163A1 (en) 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
WO1997020933A2 (en) 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
BR9709529A (pt) 1996-06-06 1999-08-10 Smithkline Beecham P L C Socie Fragmentos de leptina (proteína ob)
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
WO1998016545A1 (en) 1996-10-11 1998-04-23 Eli Lilly And Company Therapeutic proteins
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
CA2337667C (en) 1998-08-10 2008-04-29 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034885A2 (en) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Biologically active peptide fragments of ob protein
JPH093098A (ja) * 1995-05-05 1997-01-07 F Hoffmann La Roche Ag 組換え肥満(ob)蛋白
WO1997024440A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
WO1998024896A2 (en) * 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteins of obese protein

Also Published As

Publication number Publication date
EP1121155A2 (en) 2001-08-08
CA2345027C (en) 2011-07-05
AU1447500A (en) 2000-05-01
JP2002527052A (ja) 2002-08-27
ATE463260T1 (de) 2010-04-15
WO2000021574A3 (en) 2000-08-17
US6420339B1 (en) 2002-07-16
DE69942231D1 (de) 2010-05-20
WO2000021574A2 (en) 2000-04-20
AU757860B2 (en) 2003-03-06
CA2345027A1 (en) 2000-04-20
EP1121155B1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
US6420339B1 (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP5334347B2 (ja) 化学的に修飾した新規なエリスロポエチン刺激タンパク質組成物および方法
DE69737266T2 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
DE69509628T2 (de) N-terminal chemisch modifizierte protein-zusammensetzungen und methoden
US7112659B2 (en) OB fusion protein compositions and methods
DE69631544T2 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
EP1090645B1 (en) Oral delivery of chemically modified proteins
AU6028396A (en) Ob protein compositions and method
TW200418507A (en) Polymer conjugates of interferon-beta with enhanced biological potency
WO1995032003A1 (en) Modified insulin-like growth factors
AU6048294A (en) Modified insulin-like growth factors
JP2011132248A (ja) インターフェロンβを用いる慢性炎症性脱髄性多発性ニューロパシーの治療
TW524806B (en) Chemical modification of proteins to improve biocompatibility and bioactivity
JP2023083380A (ja) インターロイキン-22の治療用誘導体
EP1107793B1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
JP2006513990A5 (cg-RX-API-DMAC7.html)
MX2010010953A (es) Hormona de crecimiento modificada con glicol de polietileno de doble cadena, metodo de preparacion y aplicación del a misma.
WO2004083242A1 (en) Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
MXPA01003764A (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU2004201326B2 (en) Dextran-Leptin Conjugates, Pharmaceutical Compositions and Related Methods
HK1036214B (en) Oral delivery of chemically modified proteins
AU4866700A (en) OB protein compositions and method
AU2645100A (en) Methods of reducing or maintaining reduced levels of blood lipids using OB protein compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111018

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141104

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4854851

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term